ClinicalTrials.gg
RecruitingNCT05390840Updated Mar 13, 2024

A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)

A Phase 2 interventional study of MG-O-1002 and Placebo in Age-Related Macular Degeneration, sponsored by Theratocular Biotek Co.. Recruiting at 6 sites in Thailand. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Theratocular Biotek Co. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

A 2 parts Phase II study to investigate the effect on central macular thickness of treatment with MG-O-1002 eye drops in participants aged over 45 with neovascular age-related macular degeneration (nAMD)

Read the detailed description

Neovascular Age-related Macular Degeneration (nAMD) is a serious eye disease and a leading cause of irreversible blindness primarily in the older population. Current treatment with anti-vascular endothelial growth factor (VEGF), while effective, requires intravitreal injection meaning administration that needs to be performed by a specialist ophthalmologist and carries procedural risks. MG-O-1002 can be administered as a topical eye drop providing a potentially safer option that can be self-administered increasing accessibility. This study will evaluate the efficacy and safety of topical ocular use of MG-O-1002 in participants with nAMD.

02

Conditions studied

  • Age-Related Macular Degeneration
03

In context

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

This study's planned enrollment of 36 is below the median of 56 across 986 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Theratocular Biotek Co. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part 1:

  1. Adults aged 45 years or older with a diagnosis of nAMD
  2. Diagnosis in the study eye of active, pathologic, newly diagnosed and treatment naïve (i.e., no previous anti-VEGF treatment or other surgery in the study eye)
  3. Visual acuity from 20/25 to 20/200 in the study eye
  4. Total lesion size (including neovascularization, blood) ≦12 disc areas (30.5 mm2) as assessed by Fluorescein Angiography.
  5. Demonstrate the ability, or have a family member who is willing and able to, instill topical ocular drops in the study eye.
  6. Ability to give written and comply with study procedures.

Part 2:

  1. Adults aged 45 years or older with a diagnosis of nAMD.
  2. Participant with nAMD previously treated with 3 injections of Aflibercept within the preceding 4 months, and received the last injection within 30 to 21 days before visit 1 of this study.
  3. Demonstrate the ability, or have a family member who is willing and able to, instil topical ocular drops in the study eye.
  4. Ability to give written informed consent and comply with study procedures.

Exclusion criteria

Exclusion Criteria:

Part 1:

  1. Prior use within the last 2 months, or a high possibility of requiring treatment with anti-VEGF therapy (except the study drug) in both eyes during the study.
  2. Abnormal regions identified by Fundus Autofluorescence (FAF) and Optical Coherence Tomography (OCT) involving the center of the fovea are caused by retinal pigment epithelium (RPE) atrophy, RPE tear, photoreceptor attenuation, or fibrosis/scar tissue.
  3. Significant retinal serous pigment epithelial detachment (PED) involving the fovea.
  4. History of, or current clinical evidence in the study eye of aphakia, diabetic macular edema, any ocular inflammation or infection, pathological myopia, retinal detachment, advanced glaucoma, and/or significant media opacity, including cataract.
  5. History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
  6. Uncontrolled hypertension despite the use of antihypertensive medications.
  7. Diagnosis of Type 1 or Type 2 diabetes.
  8. Use of medications that in the opinion of the Investigator could interfere with study results.
  9. Participation in any drug or device study, systemic or ocular, within the past 3 months.
  10. Women who are pregnant or breast feeding.
  11. Women of who are not using an effective form of .
  12. Known serious allergies or to the fluorescein dye used in angiography, or to the components of the MG-O-1002 formulation, or to topical anesthetics.
  13. In the opinion of the investigator, subject who is not suitable for or not likely be benefited from the study treatment.

Part 2:

  1. More than 30 days between 3rd injection of Aflibercept and Visit 1.
  2. Patients who have received 3 injections of Aflibercept within the last 3 months and need continued treatment in the fellow eye.
  3. Significant retinal serous pigment epithelial detachment (PED), atrophy, or fibrosis/scar involving the fovea.
  4. History or evidence of the following surgeries in the study eye: penetrating keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within 3 months of Screening.
  5. Active intraocular inflammation or uveitis or scleritis or episcleritis in the study eye or ocular or periocular infection in either eye.
  6. Uncontrolled hypertension despite the use of antihypertensive medications.
  7. Diagnosis of Type 1 or Type 2 diabetes.
  8. Use of medications that in the opinion of the Investigator could interfere with study results.
  9. Participation in any investigational drug or device study, systemic or ocular, within the past 3 months.
  10. Women who are pregnant or breast feeding.
  11. Women of child-bearing potential who are not using an effective form of birth control.
  12. Known serious allergies or hypersensitivity to the fluorescein dye used in angiography, or to the components of the MG-O-1002 formulation, or to topical anesthetics.
  13. In the opinion of the investigator, subject who is not suitable for or not likely be benefited from the study treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Part 1 (MG-O-1002)

    Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular

    Drug: MG-O-1002

  • Placebo comparator
    Part 2 (MG-O-1002 or Placebo)

    Arm 1: Drug: MG-O-1002; Dose level: 0.8%; Dosage form: ophthalmic solution; Route of administration: topical ocular Arm 2: Drug: Placebo; Dosage form: ophthalmic solution; Route of administration: topical ocular

    Drug: MG-O-1002 · Other: Placebo

Interventions

  • DrugMG-O-1002

    MG-O-1002 ophthalmic solution in one concentration (0.8%) ocular administration 3 drops in study eye

  • OtherPlacebo

    The placebo is 0.9% saline ocular administration 3 drops in study eye

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in central macular thickness over 12 weeks.

    Time frame: up to 12 weeks

Secondary outcomes

  1. Mean change from baseline in Best-Corrected Visual Acuity over 12 weeks

    Time frame: up to 12 weeks

  2. Mean Change from baseline in Visual Field over 12 weeks

    Time frame: up to 12 weeks

  3. Mean change from baseline in total area of Choroidal Neovascularization (CNV) over 12 weeks

    Time frame: up to 12 weeks

  4. The number of patients needing rescue treatment within 12 weeks

    Time frame: up to 12 weeks

  5. The time to rescue treatment for needed patients within 12 weeks

    Time frame: up to 12 weeks

  6. Incidence and severity of ocular and systemic adverse events

    Time frame: up to 12 weeks

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Mar 2024, 19 months after the start.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 19 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
May 25, 2022
StartActual
Aug 9, 2022
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05390840
Lead sponsor
Theratocular Biotek Co.
Responsible party
Sponsor
First posted
May 25, 2022
Start date
Aug 9, 2022
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Mar 13, 2024

Study contacts

William Chen
Contact
william.chen@metagone.com.tw
2-2790-6566 ext. +886
Samjay Lin
Contact
samjay@metagone.com.tw
2-2790-6566 ext. +886

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion